The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of major adverse cardiovascular (CV) events, making it the “first and only oral diabetes treatment approved with this indication”, according to the manufacturer.
This means the therapy is now authorised for the treatment of heart attack, stroke or death due to a cardiovascular cause in adults with type 2 diabetes (T2D) who have established CV disease.
Reageer